Neuroregeneration

Neuroregeneration refers to the regrowth or repair of the nervous system or its components tissues, cells or cell products. Such mechanisms may include remyelination, generation of new neurons, glia, axons, myelin or synapses. Neuroregeneration differs between the Peripheral Nervous System (PNS) and the Central Nervous System (CNS) by the functional mechanisms and especially, the extent and speed.

Additional recommended knowledge

Safe Weighing Range Ensures Accurate Results

Daily Sensitivity Test

Don't let static charges disrupt your weighing accuracy

Neuroregeneration in the Peripheral Nervous System

Neuroregeneration in the PNS occurs to a significant degree.¹

In the PNS, the myelin sheath surrounding axons is maintained and generated by Schwann cells.

Neuroregeneration in the Central Nervous System

The ability of the CNS to generate new neurons or to repair axons following trauma is very limited, especially when compared to the abilities of the PNS¹ . The environment within the CNS, especially following trauma, counteracts the repair of myelin and neurons. As growth factors are not expressed or re-expressed, glial scars rapidly form, and the glia and myelin actually produce factors that inhibit remyelination and axon repair.^1,2,3,4

Neuroregeneration in Disease

Neurodegeneration is a symptom of Multiple Sclerosis, and following episodes of autoimmune attack on the nervous system, it is possible to have neuroregeneration occurring, which may result in repairing the damage dealt during the episode.

Neuroregenerative Therapies

A direction of research is towards the use of drugs that target remyelinating inhibitor proteins, or other inhibitors or neuroregeneration 3. Possible strategies include vaccination against these proteins (active immunisation), or treatment with previously created antibodies (passive immunisation). These strategies appear promising on animal models with experimental autoimmune encephalomyelitis (EAE), a model of MS.³

Proteins of Oligodendritic or Glial Debris Origin Responsible for Neuroregeneration

• NOGO –The protein family Nogo, particularly Nogo-A, has been identified as an inhibitor of remyelination in the CNS, especially in autoimmune mediated demyelination, such as found in Experimental Autoimmune Encephalomyelitis (EAE) and Multiple Sclerosis (MS).^1,3 Nogo A functions via either its amino-Nogo terminus through an unknown receptor, or by its Nogo-66 terminus through NgR1, p75, TROY or LINGO1¹. Antagonising this inhibitor results in improved remyelination,^1,3 as it is involved in the RhoA pathway (see below).

• MAG –Myelin Associated Glycoprotein acts via the receptors NgR2, GT1b, NgR1, p75, TROY and LINGO11.

• OMgp –Oligodendrocyte Myelin glycoprotein

• Ephrin B3 functions through the EphA4 receptor and inhibits remyelination.¹

• Sema 4D functions through the PlexinB1 receptor and inhibits remyelination.¹

Proteins of Astrocytic Origin Responsible for Neuroregeneration

• CSPGs- Chondroitin Sulfate ProteoGlycans act upon the RhoA pathways through an unknown receptor. Following trauma to the CNS, the astrocyte number around the trauma site rapidly increases, and thus the proteins expressed by the astrocytes, such as CSPGs concentrate.¹

RhoA Pathway

Molecules act on various receptors, such as NgR1, LINGO1, p75, TROY and other unknown receptors (eg. by CSPGs), which stimulates RhoA. RhoA activates ROCK (RhoA kinase) which stimulates LIM kinase, which then stimulates Cofilin, which effectively re-organises the Actin cytoskeleton of the cell¹. In the case of neurons, activation of this pathway results in growth cone collapse,^1,3 therefore inhibits the growth and repair of neural pathways and axons. Inhibition of this pathway by its various components usually results in some level of improved remyelination.^1,2,3,4

References

• YIU, G. & ZHIGANG, H. (2006). Glial inhibition of CNS axon regeneration. Nature Reviews Neuroscience, 7, 617-627.

• BRADBURY, E.J., MCMAHON, S.B. (2006). Spinal cord repair strategies: why do they work? Nature Reviews Neuroscience, 7, 644-653.

• KARNEZIS, T., MANDEMAKERS, W., MCQUALTER, J.L., ZHENG, B., HO, P.P., JORDAN, K.A., MURRAY, B.M., BARRES, B., TESSIER-LAVINGE, M., BERNARD, C.C.A. (2004). The neurite outgrowth inhibitor Nogo A is involved in autoimmune-mediated demyelination. Nature Neuroscience, 7, 736-744.

• BREGMAN, B.S., KUNKEL-BAGDEN, E., SCHNELL, L., DAI, H.N., GAO, D., SCHWAB, M.E. (1995). Recovery from spinal cord injury mediated by antibodies to neurite growth inhibitors. Nature, 378, 498-501.

Additional reading

MONNIER, P.P., SIERRA, A., SCHWAB, J.M., HENKE-FAHLE, S., MUELLER, B.K. (2003). The Rho/ROCK pathway mediates neurite growth-inhibitory activity associated with the chondroitin sulfate proteoglycans of the CNS glial scar. Molecular and Cellular Neuroscience, 22, 319-330

NISHIO, Y., KODA, M., KITAJO, K., SETO, M., HATA, K., TANIGUCHI, J., MORIYA, H., FUJITANI, M., KUBO, T., a, YAMASHITA, T. (2006). Delayed treatment with Rho-kinase inhibitor does not enhance axonal regeneration or functional recovery after spinal cord injury in rats. Experimental Neurology, 200, 392-397.

DERGHAM, P., ELLEZAM, B., ESSAGIAN, C., AVEDISSIAN, H., LUBELL, W.D., MCKERRACHER, L. (2002). Rho signaling pathway targeted to promote spinal cord repair. Journal of Neuroscience, 22, 2570-6577.

WEIDER, N., NER, A., SALIMI, N., TUSZYNSKI, M.H. (2001). Spontaneous corticospinal axonal plasticity and functional recovery after adult central nervous system injury. Proceedings of the National Academy of Sciences. 98, 3513–3518

BASSO, M., FISHER, L.C., ANDERSON, A.J., JAKEMAN, L.B., MCTIGUE, D.M., and POPOVICH, P.G. (2006). Basso Mouse Scale for Locomotion Detects Differences in Recovery after Spinal Cord Injury in Five Common Mouse Strains. Journal of Neurotrauma, 23, 635-659.

See also

• Nerve regeneration